NDA 220641 is the FDA application for LIFYORLI (relacorilant). The FDA's Orange Book lists the applicant of record as CORCEPT THERAPEUTICS INC and the first approval on it as Mar 25, 2026. Code name used in development: CORT125134. Owner today: Corcept Therapeutics Incorporated (Nasdaq: CORT).
Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 220641 · Orange Book NDA 220641
| Brand name (FDA) | LIFYORLI Orange Book trade name: LIFYORLI |
|---|---|
| Active ingredient (FDA) | RELACORILANT |
| Code name | CORT125134 Source: Corcept Therapeutics press release, Nov 2, 2017 “relacorilant (the newly-approved generic name for CORT125134)” |
| FDA applicant of record | CORCEPT THERAPEUTICS INC FDA Orange Book data files as of Nov 13, 2026 |
|---|---|
| Owner today | Corcept Therapeutics Incorporated (CORT) Source: Corcept Therapeutics press release, Mar 25, 2026 “Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery” |
| No. | Trade name | Form; route | Strength | Approved |
|---|---|---|---|---|
| 001 | LIFYORLI (COPACKAGED) | CAPSULE;ORAL | 100MG;25MG | Mar 25, 2026 |
Drug page: /drug/relacorilant
Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.